A Direct Rapid Phenotypic Antimicrobial Susceptibility Test Enables Early Selection of Optimal Antibiotics to Treat Bacteremia in COVID-19 Patients
1
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background: Co-infection with bacteria and severe acute respiratory syndrome coronavirus 2 may result in greater use of healthcare resources and a poor prognosis. Therefore, early selection and use of optimal antibiotics are essential. The direct rapid antibiotic susceptibility test (dRAST) can detect antibiotic resistance within 6 h of a Gram smear result. This study aimed to assess the effectiveness of dRAST for improving early selection of appropriate antibiotics for coronavirus disease 2019 (COVID-19) patients with bacteremia. Materials and Methods: This retrospective study included 96 blood culture-positive COVID-19 patients. Bacterial isolates and antimicrobial resistance profiles of each case were evaluated. Cases were divided into two groups based on whether they underwent conventional antibiotic susceptibility test (AST) or dRAST. The time to optimal targeted treatment for the two groups was investigated and compared. In addition, we examined the proportion of cases for which appropriate antibiotics were selected and broad spectrum antibiotics were administered at 72 h from blood sample collection. Results: The mean time to optimal targeted antibiotic treatment was shorter for the dRAST group [55.7; standard deviation (SD), 28.7 vs. 92.3; SD, 51.1 h; P = 0.041]. The proportion of cases receiving optimal targeted antibiotics 72 h after blood collection for culture was higher [6/10 (60.0%) vs. 10/25 (40.0%)] and the percentage receiving broad spectrum antibiotics at 72 h was lower [6/10 (60.0%) vs. 19/25 (76.0%)] in the dRAST group than in the conventional AST group. In terms of microbiology profile, the contamination rate was high (35.5%) and multidrug-resistant strains were common (63.2%) in COVID-19 patients with bacteremia. Conclusion: Application of dRAST for selection of antibiotics to treat bacteremia in COVID-19 patients may enable earlier and optimal treatment. The high incidence of contamination and resistant organisms in blood cultures from COVID-19 patients suggest that dRAST may speed up appropriate targeted treatment.
Abstract
Background: Co-infection with bacteria and severe acute respiratory syndrome coronavirus 2 may result in greater use of healthcare resources and a poor prognosis. Therefore, early selection and use of optimal antibiotics are essential. The direct rapid antibiotic susceptibility test (dRAST) can detect antibiotic resistance within 6 h of a Gram smear result. This study aimed to assess the effectiveness of dRAST for improving early selection of appropriate antibiotics for coronavirus disease 2019 (COVID-19) patients with bacteremia. Materials and Methods: This retrospective study included 96 blood culture-positive COVID-19 patients. Bacterial isolates and antimicrobial resistance profiles of each case were evaluated. Cases were divided into two groups based on whether they underwent conventional antibiotic susceptibility test (AST) or dRAST. The time to optimal targeted treatment for the two groups was investigated and compared. In addition, we examined the proportion of cases for which appropriate antibiotics were selected and broad spectrum antibiotics were administered at 72 h from blood sample collection. Results: The mean time to optimal targeted antibiotic treatment was shorter for the dRAST group [55.7; standard deviation (SD), 28.7 vs. 92.3; SD, 51.1 h; P = 0.041]. The proportion of cases receiving optimal targeted antibiotics 72 h after blood collection for culture was higher [6/10 (60.0%) vs. 10/25 (40.0%)] and the percentage receiving broad spectrum antibiotics at 72 h was lower [6/10 (60.0%) vs. 19/25 (76.0%)] in the dRAST group than in the conventional AST group. In terms of microbiology profile, the contamination rate was high (35.5%) and multidrug-resistant strains were common (63.2%) in COVID-19 patients with bacteremia. Conclusion: Application of dRAST for selection of antibiotics to treat bacteremia in COVID-19 patients may enable earlier and optimal treatment. The high incidence of contamination and resistant organisms in blood cultures from COVID-19 patients suggest that dRAST may speed up appropriate targeted treatment.
참고문헌 (30)
- "WHO coronavirus disease (COVID-19) dashboard"[URL]
- Kim Sun Bean, "Revised Korean Society of Infectious Diseases", National Evidence-based Healthcarea Collaborating Agency Guidelines on the Treatment of Patients with COVID-19, 2021, pp.53(1), 166~219[DOI]
- Peck Kyong Ran, "Collaborative Response to COVID-19 Pandemic, and Development of Treatment Guidelines", Infection and Chemotherapy, 53(1), pp.151~154 (2021), 대한감염학회[DOI]
- Pierce J, "COVID-19 and antimicrobial stewardship : lessons learned, best practices, and future implications", Int J Infect Dis, 113, pp.103~108 (2021)
- Beadling C, "How do viral infections predispose patients to bacterial infections", Curr Opin Infect Dis, 17, pp.185~191 (2004)
- Jia L, "Mechanisms of severe mortality-associated bacterial co-infections following influenza virus infection", Front Cell Infect Microbiol, 7, pp.338~ (2017)
- Feng Y, "COVID-19 with different severities : A multicenter study of clinical features", Am J Respir Crit Care Med, 201, pp.1380~1388 (2020)
- Sepulveda J, "Bacteremia and blood culture utilization during COVID-19 surge in New York City", J Clin Microbiol, 58, pp.e00875~e00920 (2020)
- Lansbury L, "Co-infections in people with COVID-19 : a systematic review and meta-analysis", J Infect, 81, pp.266~275 (2020)
- Ohki R, "Increase of blood culture contamination during COVID-19pandemic. A retrospective descriptive study", Am J Infect Control, 49, pp.1359~1361 (2021)
- Yu D, "Low prevalence of bloodstream infection and high blood culture contamination rates in patients with COVID-19", PLoS One, 15, pp.e0242533~ (2020)
- LeRose J, "502. The impact of combating COVID-19 on blood culture contamination and central line associated bloodsteam infection rates", Open Forum Infect Dis, 7(Suppl 1), pp.S316~S317 (2020)
- Sieswerda E, "Recommendations for antibacterial therapy in adults with COVID-19-an evidence based guideline", Clin Microbiol Infect, 27, pp.61~66 (2021)
- Langford BJ, "Bacterial co-infection and secondary infection in patients with COVID-19 : a living rapid review and metaanalysis", Clin Microbiol Infect, 26, pp.1622~1629 (2020)
- Al-Hadidi SH, "The spectrum of antibiotic prescribing during COVID-19 pandemic : A systematic literature review", Microb Drug Resist, 27, pp.1705~1725 (2021)
- Rose AN, "Trends in antibiotic use in United States hospitals during the coronavirus disease 2019 pandemic", Open Forum Infect Dis, 8, pp.ofab236~ (2021)
- Karataş M, "Secondary bacterial infections and antimicrobial resistance in COVID-19: comparative evaluation of pre-pandemic and pandemic-era, a retrospective single center study", Ann Clin Microbiol Antimicrob, 20, pp.51~ (2021)
- Polly M, "Impact of the COVID-19pandemic on the incidence of multidrug-resistant bacterial infections in an acute care hospital in Brazil", Am J Infect Control (2021)
- Miyagami T, "Delayed treatment of bacteremia during the COVID-19 pandemic", Diagnosis(Berl), 8, pp.327~332 (2021)
- Ferrer R, "Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour : results from a guideline-based performance improvement program", Crit Care Med, 42, pp.1749~1755 (2014)
- Barenfanger J, "Clinical and financial benefits of rapid bacterial identification and antimicrobial susceptibility testing", J Clin Microbiol, 37, pp.1415~1418 (1999)
- Choi J, "Direct, rapid antimicrobial susceptibility test from positive blood cultures based on microscopic imaging analysis", Sci Rep, 7, pp.1148~ (2017)
- Kim JH, "Enhanced antimicrobial stewardship based on rapid phenotypic antimicrobial susceptibility testing for bacteraemia in patients with haematological malignancies : a randomized controlled trial", Clin Microbiol Infect, 27, pp.69~75 (2021)
- Kim JH, "Direct rapid antibiotic susceptibility test(dRAST)for blood culture and its potential usefulness in clinical practice", J Med Microbiol, 67, pp.325~331 (2018)
- Clerc O, "Impact of matrix-assisted laser desorption ionization time-of-flight mass spectrometry on the clinical management of patients with Gram-negative bacteremia : a prospective observational study", Clin Infect Dis, 56, pp.1101~1107 (2013)
- Clinical and Laboratory Standards Institute (CLSI), "Performance standards for antimicrobial susceptibility testing. 26th ed. CLSI upplement M100-S28", CLSI, ~ (2018)
- Magiorakos AP, "Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria : an international expert proposal for interim standard definitions for acquired resistance", Clin Microbiol Infect, 18, pp.268~281 (2012)
- Kim NH, "Effect of routine sterile gloving on contamination rates in blood culture : a cluster randomized trial", Ann Intern Med, 154, pp.145~151 (2011)
- Kim JH, "Prospective evaluation of a rapid antimicrobial susceptibility test(QMAC-dRAST)for selecting optimal targeted antibiotics in positive blood culture", J Antimicrob Chemother, 74, pp.2255~2260 (2019)
- Apisarnthanarak A, "Strategy to limit multidrug-resistant Acinetobacter baumannii transmission in a cohort coronavirus disease 2019(COVID-19)critical care unit", Infect Control Hosp Epidemiol, pp.1~2 (2021)